Not all GTRs are equal.
Right, but Dr. Ashkan had been using 5-ala since 2009. Unless he is someone prone to embellishment, which I do not believe, he is probably seeing that contrast (still blinded) of an even more complete total resection (not all GTRs are equal) likely combined with DCVax-L therapy. A long time ago, I told Pyrr DCVax-L is not the strongest tool NWBO has available in its tool kit, but it is the safest. Because of that, better GTRs are going to produce better results when combined with DCVax-L. Why? Because, imo, from some old research and inferences I made a long time ago, DCVax-L is best at killing cancer cells on the move, aka: mesenchymal cells. When you resect an even greater number of cells locally, the likely remainder are individual and small groupings of ambulatory cancer cells looking for a new home to set up shop. The remaining non-mesenchymal cells are also more vulnerable because the previous immunosuppressive tumor microenvironment is temporarily or in some cases permanently disabled, allowing the immune system to target these less mutated cells as well.